#151
|
||||
|
||||
Öèòàòà:
Äà, ñ ïðèëè÷íûìè ó÷åáíèêàìè ïî òåìå "äèñáàêòåðèîç" êàê ðàç-òàêè è ïðîáëåìû. Àíãëîÿçû÷íûå ìåäèöèíñêèå êíèæêè - âåùü õîðîøàÿ, íî íå èìåþùàÿ çàêîííîé ñèëû íà ýòèõ çåìëÿõ. Äà è äàëåêî íå âñå âðà÷è èõ ÷èòàþò. ×òî æå êàñàåòñÿ îòå÷åñòâåííûõ ïðèêàçîâ, ìåòîäè÷åê è êíèæåê, òî êàê ðàç îíè-òî èçðÿäíî è ïîïóëÿðèçîâàëè ýòîò òåðìèí ó íàñ, òóò Âû ïðàâû. Âïðî÷åì, ýòî äàëåêî íå ñàìàÿ îïàñíàÿ èç èìåþùèõñÿ ó íàñ õèìåð |
#152
|
||||
|
||||
Ó÷åáíèêè â ëþáîì âèäå íå èìåþò çàêîííîé ñèëû íà ëþáûõ çåìëÿõ. Èìåþò ñèëó íîðìàòèâíûå àêòû.
__________________
Lead, follow, or get out of the way. — Thomas Paine |
#153
|
|||
|
|||
Íó òóò ïîíÿòíî, ÷òî èìåë â âèäó àâòîð. Íàñ ðåãóëÿðíî ïûòàþòñÿ òêíóòü íîñîì â ÎÑÒ ïî äèñáàêòåðèîçó ó äåòåé. Åñòü æå òàêîé "äîêóìåíò"!
|
#154
|
|||
|
|||
|
#155
|
|||
|
|||
Âîîáùå.êîíå÷íî.ïîñëå ïðî÷òåíèÿ äèñêóññèè,ññûëîê íà÷àëà ñîìíåâàòüñÿ â íàëè÷èè äèñáàêòåðèîçà êàê òàêîâîãî.
Æàëü,÷òî íàñ ó÷àò íåñîâñåì òàê.êàê íóæíî.Íå îðèåíòèðóþòñÿ íà çàðóáåæíóþ ïðàêòèêó,íà äîêàçàòåëüíóþ áàçó. Ïîêà íå áóäåò åäèíîé ó÷åáíîé áàçû,ñîõðàíèòüñÿ ïóòàíèöà è òåðìèíîëîãèè, è â äèàãíîñòèêå. |
#156
|
||||
|
||||
Ó÷àò â øêîëå, ó÷àò â øêîëå, ó÷àò â øêîëå...
1. Ñïðàâî÷íèê ïåäèàòðà. Ïîä ðåä. ïðîô. Øàáàëîâà Í.Ï. ÑÏá, 2006 ñòð.473 Äèñáàêòåðèîç êèøå÷íèêà. 2. Èíôåêöèîííûå áîëåçíè ó äåòåé. Ïîä ðåä. ïðîô. Òèì÷åíêî Â.Í. ÑÏá, 2006. ñòð.368 Äèñáàêòåðèîç êèøå÷íèêà. 3. Ïåäèàòðè÷åñêàÿ ãàñòðîýíòåðîëîãèÿ. ïðîô Áåëîóñîâ Þ.Â. Ìîñêâà, 2006. ñòð 553 Äèñáàêòåðèîç êèøå÷íèêà. 4. Ãàñòðîýíòåðîëîãèÿ äåòñêîãî âîçðàñòà. Ïîä ðåä. ïðîô. Áåëüìåðà Ñ.Â., ïðîô. Õàâêèíà À.È. Ìîñêâà, 2003. ñòð. 198 Äèñáàêòåðèîç êèøå÷íèêà. 5. Ãàñòðîýíòåðîëîãèÿ è ãåïàòîëîãèÿ. Ïîä ðåä. ïðîô. Êàëèíèíà À.Â., ïðîô. Õàçàíîâà À.È. Ìîñêâà, 2007. ñòð. 256 6. Îñíîâû ôàðìàêîòåðàïèè äåòåé è âçðîñëûõ: ðóêîâîäñòâî äëÿ âðà÷åé. Ïðîô. Ìèõàéëîâ È.Á. ÑÏá, 2007. ñòð. 531. 7. Ñòàíäàðòû äèàãíîñòèêè è ëå÷åíèÿ âíóòðåííèõ áîëåçíåé. 3-å èçä. Ïðîô. Øóëóòêî Á.È., 2005. ñòð.301. Äà... äèñáàêòåðèîç â Ðîññèè ëå÷èòü âñ¸ ðàâíî áóäóò... íàâåðíîå åùå î÷åíü äîëãî... |
#157
|
||||
|
||||
À åñëè ó÷åñòü, ÷òî ìèêðîîðãàíèçìû åñòü âåçäå è âñå ñâîè "ëè÷íî-ñïåöèôè÷åñêèå", è íà âñåõ èõ ïåðèîäè÷åñêè (äà è âñåãäà - ñ ó÷¸òîì îñîáåííîñòåé ñîâðåìåííîé ïðîìûøëåííîñòè, èñïîëüçóþùåé àíòèáèîòèêè äëÿ ëó÷øåé ñîõðàííîñòè ïðîäóêòîâ) äåéñòâóþò àíòèáèîòèêè.... Ïîëó÷èòñÿ íå òîëüêî äèñá. êèøå÷íèêà, íî è äèñá.êîæè, ãëàçà, íîñà, óõà (ëåâîãî è ïðàâîãî) è òûäû è òûïû.
È ãäå íîðìà, è ãäå äèñáàêòåðèîç? Äóìàþ, åñëè ÷åëîâåê ÷óâñòâóåò ñåáÿ õîðîøî, íå÷åãî èñêàòü ïðîáëåì. Íó äðóæèò îí ñî ñâîåé "äèñáàêòåðèîçíîé" ôëîðîé, åìó õîðîøî è ôëîðå õîðîøî, íå íàäî ïîñòîðîííèì âìåøèâàòüñÿ â ëè÷íûå îòíîøåíèÿ õîçÿèí-ìèêðîá. Êàê-òî íåêóëüòóðíî |
#158
|
||||
|
||||
December 2, 2010 — The currently known health benefits of probiotics and prebiotics, including those added to infant formula and other food products for children, are reviewed in an American Academy of Pediatrics (AAP) report published online November 29 in Pediatrics.
"Efforts to optimize the intestinal microbial milieu have increased the interest in adding probiotics and prebiotics to nutritional products. As with antibiotics, the use and efficacy of probiotics and prebiotics should be supported by evidenced-based medicine," write Frank R. Greer, MD, FAAP, and Dan W. Thomas, MD, FAAP, and the Committee on Nutrition; Section on Gastroenterology, Hepatology, and Nutrition. "The purpose of this clinical report is to review the medical uses of probiotics and prebiotics and to summarize what is currently known about their health benefits as dietary supplements added to food products marketed to children, including infant formula. The guidance in this report will help pediatric health care providers to make appropriate decisions regarding the usefulness and benefit of probiotics and prebiotics for their patients." Probiotics are supplements or foods containing viable microorganisms capable of changing host microflora. Randomized clinical trials (RCTs) have shown probiotics to be modestly effective in treating acute viral gastroenteritis in healthy children. For otherwise healthy children and infants with diarrhea from acute viral gastroenteritis, giving probiotics early in the course may reduce the duration of diarrhea by 1 day. Despite the lack of evidence for the efficacy of probiotics in treating antibiotic-associated diarrhea in otherwise healthy children, RCTs have shown that they are modestly effective for prevention. Although more studies are needed, some evidence supports probiotic use to prevent necrotizing enterocolitis in very-low-birth-weight infants (birth weight between 1000 and 1500 g). Before probiotics can be recommended for treatment of irritable bowel syndrome, Crohn's disease, colic, and constipation, or for prevention of common infections and allergy in children, additional studies are needed. However, preliminary results were encouraging in RCTs in which probiotics were used to treat childhood Helicobacter pylori gastritis, irritable bowel syndrome, chronic ulcerative colitis, and infantile colic, or to prevent childhood atopy. Evidence to date has not shown a benefit of probiotics in treating or preventing human cancers or in treating pediatric Crohn's disease. Routine use of probiotics or prebiotics added to infant formula and other foods intended for consumption by children is not supported by currently available evidence of clinical efficacy, but these formulas do not appear to harm healthy infants and children. However, probiotics should not be administered to children with chronic or serious diseases, including children who are immunocompromised, chronically debilitated, or who have indwelling medical devices. Prebiotics are supplements or foods containing a nondigestible food ingredient that selectively promotes growth and/or activity of indigenous probiotic bacteria. Prebiotics found in human milk may help reduce common infections and atopic eczema in healthy infants, but more evidence is needed before adding prebiotics to infant formula can be recommended. íåñê/ ìîìåíòîâ èç ñòàòüè: Ðàíäîìèçèðîâàííûå êëèíè÷åñêèå èññëåäîâàíèÿ (RCTs) ïîêàçàëè ïðîáèîòèêè ïîêàçàëè ñêðîìíóþ ýôôåêòèâíîñòü ïðè ëå÷åíèè îñòðîãî âèðóñíîãî ãàñòðîýíòåðèòà â çäîðîâûõ äåòÿõ. Òàê êàê èíà÷å çäîðîâûå äåòè è ìëàäåíöû ñ äèàðååé îò îñòðîãî âèðóñíîãî ãàñòðîýíòåðèòà, äàâàÿ ïðîáèîòèêè ðàíî â ëå÷åíèè ìîãóò óìåíüøèòü ïðîäîëæèòåëüíîñòü äèàðåè íà 1 äåíü. Íåñìîòðÿ íà íåõâàòêó äîêàçàòåëüñòâ ýôôåêòèâíîñòè ïðîáèîòèêîâ â ðàññìîòðåíèè ñâÿçàííîé ñ àíòèáèîòèêîì äèàðåè â îáùåì çäîðîâûõ äåòÿõ, RCTs ïîêàçàëè, ÷òî îíè ñêðîìíî ýôôåêòèâíû äëÿ åå ïðåäîòâðàùåíèÿ.Õîòÿ áîëüøå èññëåäîâàíèé íåîáõîäèìî, íåêîòîðûå äîêàçàòåëüñòâà ïîääåðæèâàþò ïðîáèîòè÷åñêîå èñïîëüçîâàíèå, ÷òîáû ïðåäîòâðàòèòü íåêðîòèçèðóþùèé ýíòåðîêîëèò ó ìëàäåíöåâ ñ"î÷åíü íèçêèì âåñîì ïðè ðîæäåíèè" (âåñ ïðè ðîæäåíèè ìåæäó 1000 è 1500 g)....Îäíàêî, ïðåäâàðèòåëüíûå ðåçóëüòàòû áûëè îáîäðèòåëüíû â RCTs, â êîòîðîì ïðîáèîòèêè èñïîëüçîâàëèñü äëÿ ëå÷åíèÿ äåòñòêîãî ãàñòðèò,âûçâàííîãî Helicobacter Ïèëîðè, ñèíäðîì ðàçäðàæåííîé òîëñòîé êèøêè, õðîíè÷åñêèé ÿçâåííûé êîëèò, è èíôàíòèëüíàÿ êîëèêà, èëè ïðåäîòâðàòèòü äåòñêèå àòîïè÷åñêèå çàáîëåâàíèÿ. Äîêàçàòåëüñòâà äî íàñòîÿùåãî âðåìåíè íå ïîêàçàëè âûãîäó ïðîáèîòèêîâ â ðàññìîòðåíèè èëè ïðåäîòâðàùåíèè ÷åëîâå÷åñêèõ ðàêîâûõ îáðàçîâàíèé èëè â ëå÷åíèè ïåäèàòðè÷åñêîé áîëåçíè Êðîíà. Îáû÷íîå èñïîëüçîâàíèå ïðîáèîòèêîâ èëè ïðåáèîòèêè, äîáàâëåííîé ê ìëàäåí÷åñêîé ôîðìóëå è äðóãèì ïðîäóêòàì, ïðåäíàçíà÷åííûì äëÿ ïîòðåáëåíèÿ äåòüìè, íå ïîääåðæàíî â íàñòîÿùåå âðåìÿ èìåþùèìñÿ äîêàçàòåëüñòâîì êëèíè÷åñêîé ýôôåêòèâíîñòè, íî ýòè ôîðìóëû, êàæåòñÿ, íå âðåäÿò çäîðîâûì ìëàäåíöàì è äåòÿì. Îäíàêî, ïðîáèîòèêàìè íåëüçÿ íàçíà÷àòü äåòÿì ñ õðîíè÷åñêèìè èëè ñåðüåçíûìè áîëåçíÿìè, âêëþ÷àÿ äåòåé, êîòîðûå ñ îñëàáëåííûì èììóíèòåòîì, õðîíè÷åñêè èñòîùåííûå |
#159
|
|||
|
|||
Ïðî÷èòàëà âñå òåìû êàñàòåëüíî äèñáàêòåðèîçà. Ïîëíîñòüþ ñîãëàñíà ñ âàøèìè äîâîäàìè è ñ÷èòàþ äèñáàêòåðèîç íåâåäîìîé çâåðóøêîé.
Ñàìà ðàáîòàþ â ïðåäñòàâèòåëüñòâå ôàðìàöåâòè÷åñêîé êîìïàíèè, êîòîðàÿ ïðåäñòàâëÿåò íà ðûíêå ëåêàðñòâåííûé ïðåïàðàò ñ ñîäåðæàíèåì l.rhamnosus R0011. Ïîýòîìó çíàêîìà ñ ýòîé äèëåìîé íå ïî íàñëûøêå. ß ñàìà êàæäûé äåíü ñòàëêèâàþñü ñ ïåäèàòðàìè, êîòîðûå "äèàãíîñòèðóþò" äèñáàêòåðèîç ïî ëàäîíè. Ñî ñòîðîíû ôàðì. êîìïàíèè ñêàæó ÷òî ïðîìîòèðóåì ïðåïàðàò äëÿ ïðîôèëàêòèêè ÀÀÄ (àññîöèèðîâàííîé ñ Cl.diff). Ê ñîæàëåíèþ ó íàñ â Óêðàèíå åå íè êà÷åñòâåííî íè êîëè÷åñòâåííî íå îïðåäåëÿþò. Íà ñêîëüêî ÿ çíàþ, â Åâðîïå åå èäåíòèôèöèðóþò ïî ÈÔÀ íà òîêñèíû. Íî ñóòü äàæå íå â ýòîì. Ìû õîòåëè ïîñìîòðåòü íàëè÷èå è ðàçâèòèå êëîñòðèäèàëüíîé èíôåêöèè â ñëåäñòâèè àíòèáèîòèêîòåðàïèè. Îêàçàëîñü ÷òî êàæäûé 5 ðåáåíîê ïîëó÷àâøèé àíòèáèîòèêîòåðàïèþ èìåë àêòèâíóþ òîêñèãåííóþ êëîñòðèäèàëüíóþ èíôåêöèþ (î ÷åì íàì ãîâîðèëè òîêñèíû). è òîëüêî 30% ñîïðîâîæäàëèñü ÀÀÄ. Ò.å. ïðîöåññ òîêñèíîíîñèòåëüñòâà áåç äèàðåè áûë äëÿ íàñ î÷åâèäåí. Òàê âîò, õîòåëà óçíàòü âàøå ìíåíèå è ìíåíèå ñïåöèàëèñòîâ Åâðîïû (ó êîòîðûõ åñòü ñèñòåìà êîíòðîëÿ äàííîé èíôåêöèè) î äàííîì ÿâëåíèè. Ñïàñèáî |
#160
|
|||
|
|||
Ïðî÷èòàëà ýòó âåòêó è ñîãëàñèëàñü, ÷òî äèñáàêòåðèîç ìû äèàãíîñòèðîâàòü, à çíà÷èò, è ëå÷èòü íå ìîæåì!
È ñåãîäíÿ ïðèõîäèò ìàìî÷êà ïîëóòîðàãîäîâàëîãî ìàëûøà ñ "àíàëèçîì íà äèñáàêòåðèîç" êîòîðûé îíè ñäàëè ñàìîñòîÿòåëüíî ïëàòíî, ïî ñîâåòó ïîäðóãè, è ñ æàëîáàìè íà æèäêèé, âîíþ÷èé, çåëåíîâàòûé ñòóë 1-2 ðàçà â ñóòêè óæå 2 ìåñÿöà!!!  "àíàëèçå", êîíå÷íî ìíîãî ðàçíûõ óñëîâíî-ïàòîãåííûõ "çâåðóøåê". Åùå â÷åðà ÿ áû ñ ðàäîñòüþ íàçíà÷èëà èì áàêòåðèîôàãè è ïðîáèîòèêè è îòïðàâèëà áû ëå÷èòüñÿ. Íî ÿ óæå íå âåðþ â ýòîò ÷óäî äèàãíîç è ìíå õî÷åòñÿ èõ äî îáñëåäîâàòü è ëå÷èòü ïðàâèëüíî. ×òî ïîñîâåòóåòå êîëëåãè? P.s. ÿ íåäàâíî íà ýòîì ñàéòå - ïðîøó ìîäåðàòîðîâ íå ðóãàòüñÿ åñëè ÷òî-òî íå òàê íàïèñàëà - ñî âðåìåíåì ðàçáèðóñü |
#161
|
||||
|
||||
Öèòàòà:
|
#162
|
|||
|
|||
Àáñîëþòíî ñ Âàìè ñîãëàñåí. Ñìîòðåòü èíäèâèäóàëüíóþ òðàíçèòíóþ ôëîðó ... çà÷åì? Íî êîëëåãè, îñîáåííî àëëåðãîëîãè-äåðìàòîëîãè òàêèì äèàãíîçîì ÷àñòåíüêî ãðåøàò ... è íàïðàâëÿþò ëå÷èòüñÿ ê ãàñòðîýíòåðîëîãó. )
|
#163
|
|||
|
|||
Õîðîøàÿ ñòàòüÿ â àâòîðèòåòíîì èñòî÷íèêè: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Òàê ÷òî, íå âñ¸ òàê ïðîñòî. |
#164
|
||||
|
||||
Öèòàòà:
À âîò ó îíêîáîëüíûõ, ó "ïîñòñåïñèñíûõ" íîâîðîæäåííûõ áûâàþò èñòèííûå äèñáàêòåðèîçû, ò.å. äèñáàêòåðèîç êàê ïðè÷èíà ïðîáëåì ñ ÆÊÒ. Ó íèõ è áèîïðåïàðàòû äàþò õîðîøèé ýôôåêò, êñòàòè. |
#165
|
||||
|
||||
Íåóæåëè â ýòîì òîïèêå ìû ðàññêàçûâàåì îá îñáåííîñòÿõ ëå÷åíèÿ îíêîáîëüíûõ ? Íåóæåëè àðåñòîâûâàåì çàäåðæàííûõ â ìàãàçèíå ñ áóòûëêîé êåôèðà ?
Ìåíÿ âñåãäà ïîðàæàë ôàíàòèçì ïðîäîëæàòåëåé äåëà Ìå÷íèêîâà - êàê òîëüêî ïîÿâÿòñÿ ãäå -òî 2-3 òåïëûõ ñëîâà ïðî êåôèð èëè ïðî áàêòåðèè â êèøå÷íèêå -áåçóìíîå ñ÷àñòüå .. Óæå è òðóï òîïèêà îñòûë - íî òðóáà çîâåò , àêòèìåëü - ôîðåâåð , äåòñêèå êàêàøêè íà äèñáàêòåðèîç - îñíîâíîå ðàçâëå÷åíèå íà ó÷àñòêå ..
__________________
Ã.À. Ìåëüíè÷åíêî |